Lawson Kroeker Investment Management Inc. NE Raises Stock Position in Bruker Corporation $BRKR

Lawson Kroeker Investment Management Inc. NE grew its stake in Bruker Corporation (NASDAQ:BRKR) by 4.5% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 217,648 shares of the medical research company’s stock after purchasing an additional 9,342 shares during the quarter. Bruker comprises about 1.7% of Lawson Kroeker Investment Management Inc. NE’s holdings, making the stock its 19th biggest holding. Lawson Kroeker Investment Management Inc. NE’s holdings in Bruker were worth $8,967,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently modified their holdings of the stock. Teacher Retirement System of Texas lifted its holdings in Bruker by 5.1% in the first quarter. Teacher Retirement System of Texas now owns 29,045 shares of the medical research company’s stock worth $1,212,000 after buying an additional 1,422 shares during the period. Fifth Third Bancorp lifted its stake in shares of Bruker by 54.2% in the 1st quarter. Fifth Third Bancorp now owns 1,109 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 390 shares during the period. Amundi lifted its stake in shares of Bruker by 373.3% in the 1st quarter. Amundi now owns 42,503 shares of the medical research company’s stock valued at $1,774,000 after purchasing an additional 33,522 shares during the period. Wealth Enhancement Advisory Services LLC boosted its position in shares of Bruker by 35.6% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 40,450 shares of the medical research company’s stock valued at $1,717,000 after purchasing an additional 10,624 shares in the last quarter. Finally, Vaughan Nelson Investment Management L.P. grew its stake in Bruker by 71.2% in the second quarter. Vaughan Nelson Investment Management L.P. now owns 1,293,645 shares of the medical research company’s stock worth $53,298,000 after purchasing an additional 537,845 shares during the period. Institutional investors own 79.52% of the company’s stock.

Insider Activity at Bruker

In related news, Director Cynthia M. Friend sold 3,535 shares of Bruker stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $32.25, for a total value of $114,003.75. Following the completion of the sale, the director directly owned 18,016 shares in the company, valued at approximately $581,016. This trade represents a 16.40% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 27.30% of the stock is owned by company insiders.

Analysts Set New Price Targets

BRKR has been the subject of several recent research reports. Bank of America lowered their price objective on Bruker from $61.00 to $50.00 and set a “buy” rating for the company in a research report on Thursday, June 26th. Barclays lowered their price target on shares of Bruker from $43.00 to $40.00 and set an “overweight” rating for the company in a research report on Thursday, October 2nd. Citigroup cut their price objective on shares of Bruker from $40.00 to $38.00 and set a “neutral” rating on the stock in a report on Monday, August 4th. Jefferies Financial Group set a $60.00 target price on shares of Bruker and gave the company a “buy” rating in a report on Monday, August 4th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Bruker in a research report on Wednesday. Five research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $51.00.

Bruker Trading Down 1.8%

Shares of NASDAQ BRKR opened at $35.28 on Friday. The firm’s 50 day moving average price is $32.98 and its 200-day moving average price is $37.15. The company has a market cap of $5.35 billion, a PE ratio of 67.85, a P/E/G ratio of 4.91 and a beta of 1.20. Bruker Corporation has a 52-week low of $28.53 and a 52-week high of $65.25. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.70 and a current ratio of 1.61.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). The firm had revenue of $797.40 million for the quarter, compared to the consensus estimate of $811.17 million. Bruker had a net margin of 2.31% and a return on equity of 17.89%. Bruker’s revenue was down .4% on a year-over-year basis. During the same period last year, the business earned $0.52 EPS. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. On average, equities research analysts expect that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, October 3rd. Stockholders of record on Tuesday, September 23rd were issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Tuesday, September 23rd. Bruker’s dividend payout ratio is presently 38.46%.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.